Samsung Galaxy Watch Gets FDA Approval for Heart Rhythm Notifications

The News: Samsung Electronics recently announced that it has received approval from the Food and Drug Administration (FDA) for its Irregular Heart Rhythm Notification (IHRM) feature. Read the Samsung Electronics Press Release for more information.

Samsung Galaxy Watch Gets FDA Approval for Heart Rhythm Notifications

Analyst Take: Samsung Electronics getting approval from the Food and Drug Administration (FDA) for irregular heart rhythm notifications (IHRN) for its Samsung Galaxy Smart Watches is an excellent move for the company. Currently, the Galaxy Watch offers different tools that help its users get a better understanding of their heart health using the Samsung BioActive Sensor such as on-demand ECG recording. The addition of the IHRN will add another element to help correlate events. According to Samsung, once the IHRN feature is activated in the Samsung Health Monitor app, the feature will check for irregular heart rhythms in the background of the Galaxy Watch’s BioActive Sensor. Thus, if a certain number of measurements are irregular, the Galaxy Watch will warn the user of AFib activity which then prompts them to take an ECG for more accurate measurements.

As much as we have seen handset devices cannibalize other long-standing devices over the years (e.g., clock radios, handset GPS, etc.), it makes sense that the wearables category (e.g., smartwatches, etc.) may follow a similar pattern or at least offer functionality that can augment treatment by adding additional insights to the physician. As an example, many people get white coat hypertension (blood pressure rises) when they enter medical settings due to anxiety which can cause inaccurate testing. Other factors include many people getting heart attacks due to higher elevations, in traffic with heavy air pollution, a diabetic eating a high sugar meal which can thicken the blood and raise blood pressure, or someone with undiagnosed sleep apnea can be at risk for AFib (atrial fibrillation). Thus, using a wearable device such as a smartwatch may offer the physician more accurate clues about a patient’s normal baseline state which can offer more effective treatments.

In the future, as more artificial intelligence is woven into devices (e.g., handsets, smartwatches, automobiles, etc.) coupled with more databases correlating information at a faster rate at the edge, it makes sense that we will continue to experience more pre-alerts that will save lives. In fact, imagine you are driving or hiking up a mountain and you start getting alerts that 10,000 people at the same elevation, weather conditions (e.g., humidity, temperature, etc.), take the same medications, and have the same body type (e.g., endomorphic, etc.) all had a life-threatening event if they proceeded forward. Do you think you’d keep going? Will you have your electronic vehicle picking up your vitals from your watch set to automatically turn around? Well, we aren’t exactly there yet but we feel like this is the direction at this point and the wearables segment will be a key part of that ecosystem.

Wrapping it up, Samsung Electronics getting FDA approval for its Samsung Galaxy Watch to get heart rhythm notifications (IHRM) is an excellent move that will not only help physicians diagnose patients more appropriately but will help patients be more proactive in self-monitoring and make the necessary adjustments where they can. The future looks brighter, healthier, and safer for consumers.

Disclosure: The Futurum Group is a research and advisory firm that engages or has engaged in research, analysis, and advisory services with many technology companies, including those mentioned in this article. The author does not hold any equity positions with any company mentioned in this article.

Analysis and opinions expressed herein are specific to the analyst individually and data and other information that might have been provided for validation, not those of The Futurum Group as a whole.

Other insights from The Futurum Group:

5G Factor Video Research Note: T-Mobile Rumored to be Exploring Partnering with Samsung for 5G Network Equipment

The Vatican’s Swiss Army Guard is Leveraging Samsung’s Knox Suite Mobile Device Management Software to Manage Devices

Samsung Galaxy A54 5G Smartphone: Stellar Features at an Affordable Price

Related Insights
Qualcomm Q4 FY 2026 Custom Silicon Drives Non-Handset Expansion
November 9, 2026

Qualcomm Q4 FY 2026: Custom Silicon Drives Non-Handset Expansion

Futurum Research analyzes Qualcomm’s Q4 FY 2026 results, including its automotive module ramp, first custom chip shipments to hyperscalers, and margin pressures as handset sales weaken....
Arm Q2 FY 2027 AGI CPU Orders Expand Data Center Opportunity
November 6, 2026

Arm Q2 FY 2027: AGI CPU Orders Expand Data Center Opportunity

Futurum Research analyzes Arm’s Q2 FY 2027 licensing gains, rising data center royalties, and how supply will shape the rollout of Arm’s own server chip....
Qualcomm Validates First HBC Silicon With an 18x Memory Bandwidth Gain Over LPDDR5X
November 3, 2026

Qualcomm Validates First HBC Silicon With an 18x Memory Bandwidth Gain Over LPDDR5X

Brendan Burke, Research Director at Futurum, examines Qualcomm's validated first-generation HBC silicon, its measured 18x bandwidth gain and 5x bandwidth per watt over HBM4, and whether stacked DRAM on compute...
ABB Q3 FY 2026 Earnings Show Record Orders Outpacing Revenue on Data Centers
November 2, 2026

ABB Q3 FY 2026 Earnings Show Record Orders Outpacing Revenue on Data Centers

Olivier Blanchard, Research Director and Practice Lead, Intelligent Devices at The Futurum Group, reviews ABB's Q3 FY 2026 earnings, record data center-led orders, the Infinitus DC launch, and the Mitsubishi...
Stellantis Q3 FY 2026 Earnings Show Cost Cuts Offsetting a Weak Europe
November 2, 2026

Stellantis Q3 FY 2026 Earnings Show Cost Cuts Offsetting a Weak Europe

Olivier Blanchard, Research Director and Practice Lead, Intelligent Devices at The Futurum Group, reviews Stellantis' Q3 FY 2026 earnings, Value Creation Program cost gains, North America's recovery, and Europe's margin...
Texas Instruments Q3 FY 2026 Earnings Beat as Data Center Sales Nearly Double
November 2, 2026

Texas Instruments Q3 FY 2026 Earnings Beat as Data Center Sales Nearly Double

Brendan Burke, Research Director, Semiconductors, Supply Chain & Emerging Tech at Futurum, reviews Texas Instruments' Q3 FY 2026 earnings, data center growth, a new industrial peak, and capacity-driven pricing gains....

Book a Demo

Welcome

The vision behind everything in Futurum’s Custom Research practice is this: research should show you what is happening, what comes next, and what to do about it. It should be personal to each audience, easy for people to grasp, and structured so LLMs can reason over it accurately. And it should be fast and turnkey; you want answers now, not another project to carry for quarters.

Whether you are defining business, channel, or go-to-market strategy; evaluating vendors or justifying ROI; or commissioning research to fill an emerging market need, we have your back, with a program that answers your questions with the objectivity and credibility to drive real decisions.

To do it, we bring unmatched data to bear: Futurum research, surveys, and market projections; validated market feeds; ETR’s 15 years of insight from 10,000 technology decision-makers; G2’s buyer and user data; and what our analysts hear every day. Add leading primary collection, from AI-moderated voice interviews to surveys and analyst-led interviews, all turnkey, and every project comes out credible, nuanced, and actionable.

And we don’t just drop the results in your lap. For internal work, we provide analyst-led sessions, interactive dashboards, and a range of formats. For market-facing work, Futurum delivers turnkey activation and amplification that actually gets seen, by people and by LLMs, through our media and share of voice. This is research that moves decisions and markets.

We will meet you wherever you are, from a fast-turn brief to a multi-year program, and shape the work to your goals, timeline, and budget. The right program for your moment.

If any of this is useful, I would love to talk.

Benjamin Brown, VP Custom Research, Futurum Research

Benjamin Brown

VP, Custom Research · The Futurum Group

Newsletter Sign-up Form

Get important insights straight to your inbox, receive first looks at eBooks, exclusive event invitations, custom content, and more. We promise not to spam you or sell your name to anyone. You can always unsubscribe at any time.

All fields are required






Thank you, we received your request, a member of our team will be in contact with you.